Composite bone implants

Patent metadata

Field	Value
Publication number	US-9901450-B2
Application number	US-201314425234-A
Country	US
Kind code	B2
Filing date	Sep 4, 2013
Priority date	Sep 4, 2012
Publication date	Feb 27, 2018
Grant date	Feb 27, 2018

Abstract

The invention provides natural multi-composite bone implants such as bone-connective tissue-bone and osteochondral implants for the replacement and/or repair of, for example and in particular a damaged or defective bone-meniscus-bone joint or a bone-patella tendon-bone joint or osteochondral lesions, methods of preparing the composites and uses thereof. The invention also provides natural or native composite bone-connective tissue-bone and osteochondral matrices or scaffolds that are substantially decellularized for subsequent transplantation/implantation.

First claim

The invention claimed is:

1. A product comprising a decellularised natural multi-composite bone transplant material characterised by the absence or substantial absence of cells in the whole composite, wherein the multi-composite bone transplant material is bone-connective tissue-bone or osteochondral, wherein the substantial absence is between 90% and up to 100% removal of cells from all parts of the multi-composite transplant product.

2. The product according to claim 1 that retains its original histoarchitecture and structural collagen composition as compared to a native fresh cellularised counterpart composite tissue.

3. The product according to claim 1 , wherein total genomic DNA (gDNA) content of all tissue types in the multi-composite product is between 0 to 10% of the native tissue.

4. The product according to claim 1 that is derived from allogenic tissue.

5. The product according to claim 1 that is derived from xenogeneic tissue selected from the group consisting of porcine, bovine or ovine tissue.

6. The product according to claim 1 , wherein the connective tissue is selected from the group consisting of ligaments, meniscus and enthesis.

7. The product according to claim 6 , wherein the ligaments are selected from the group consisting of head and neck ligaments, wrist and finger ligaments, knee ligaments, thorax ligaments, foot ligaments and pelvis ligaments.

8. The product according to claim 7 , wherein the knee ligaments are selected from the group consisting of anterior cruciate ligament (ACL), lateral collateral ligament (LCL), posterior cruciate ligament (PCL), medial collateral ligament (MCL), cranial cruciate ligament (CRCL)—quadruped equivalent of ACL, caudal eructate ligament (CACL)—quadruped equivalent of PCL and patellar ligament.

9. The product according to claim 6 , wherein the meniscus is medial meniscus tissue and the medial meniscus tissue includes attachment tissue or enthesis at either end of the meniscus attaching the meniscus to each terminal bone block.

10. A method of treatment of an individual requiring knee repair or replacement surgery comprising replacing a defective or damaged knee joint with the product comprising a decellularised natural multi-composite bone transplant material of claim 1 .

11. A method of treatment of an individual requiring patella tendon knee repair or replacement surgery comprising replacing a defective or damaged area with the product comprising a decellularised natural multi-composite bone transplant material of claim 1 .

12. A method of treatment of an individual requiring osteochondral repair or replacement surgery comprising replacing a defective or damaged area with the product comprising a decellularised natural multi-composite bone transplant material of claim 1 .

Assignees

• Univ Leeds Innovations Ltd

Inventors

• Ingham Eileen
• Jones Gemma
• Fermor Hazel
• Fisher John
• HASAN Jahid

Classifications

• A61L2430/40

  Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking · CPC title

• A61L2430/02

  for reconstruction of bones; weight-bearing implants · CPC title

• A61L27/3821

  Bone-forming cells, e.g. osteoblasts, osteocytes, osteoprogenitor cells · CPC title

• A61L27/3691

  characterised by physical conditions of the treatment, e.g. applying a compressive force to the composition, pressure cycles, ultrasonic/sonication or microwave treatment, lyophilisation · CPC title

• A61L27/3687

  characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents · CPC title